ClinicalTrials.gg
CompletedNCT04946734SPRINGUpdated Nov 12, 2026

Efficacy and Safety of PFO Closure vs Medical Therapy in Alleviating Migraine

A Phase 3 interventional study of PFO closure device and Aspirin and clopidogrel in PFO - Patent Foramen Ovale and Migraine, sponsored by Guangdong Provincial People's Hospital. Completed at 26 sites in China. Open to participants aged 16 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Guangdong Provincial People's Hospital · Phase 3, Interventional, and Treatment

How we know

Updated Nov 12, 2026Now CompletedPrimary completion moved+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
16 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Foramen Ovale, Patent with a site in China — 13 open to participants now, 13 under way, none of them phase 3. Foramen Ovale, Patent · China.

Enrollment
3rd of 14
440 · median 211
Started
2021
the only one that year
Phase 3
Only one
of the 20
Registered
5th of 20
by date
Lead sponsor
1 of 20
Guangdong Provincial People's Hospital

Among the 20 studies in Foramen Ovale, Patent with a site in China, this one is the 3rd largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2021, is the only one in phase 3, and was the 5th registered.

Foramen Ovale, Patent

137 studies on the registry are indexed under Foramen Ovale, Patent; 47 are open to participants now.

Browse Foramen Ovale, Patent studies →

Open to participants now

13 of the 20 studies in Foramen Ovale, Patent with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 34 Foramen Ovale, Patent studies recruiting now, 11 (32%) set no upper age limit and 19 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 16 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Foramen Ovale, Patent with a site in China, or all of them as a file.
02

Study summary

Migraine is a common neurological disorder that can significantly affect quality of life. Patent foramen ovale (PFO), a small opening between the upper chambers of the heart, has been associated with migraine, but whether closing the PFO can effectively relieve migraine remains uncertain.

This investigator-initiated, multicenter, randomized, open-label trial aims to evaluate the effectiveness and safety of PFO closure in patients with migraine. A total of 440 participants aged 16-60 years with migraine and PFO-associated right-to-left shunt were enrolled at 26 centers in China. Participants were randomly assigned to receive either PFO closure plus antiplatelet therapy or antiplatelet therapy alone.

The primary outcome is complete cessation of migraine during months 10-12 after randomization. Secondary outcomes include changes in migraine frequency, headache-related disability, and quality of life. Participants are followed for 12 months to assess treatment effectiveness and safety.

03

Conditions studied

  • PFO - Patent Foramen Ovale
  • Migraine
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
16 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is aged between 16 and 60 years old.
  2. Subject is diagnosed of PFO with right-to-left shunt, confirmed by Transthoracic echocardiography (TTE) or transesophageal echocardiography (TEE) with agitated saline contrast.
  3. Subject is diagnosed of right-to-left shunt, confirmed by transcranial doppler with agitated saline contrast.
  4. Subject is diagnosed of migraine without identifiable cause of headache.
  5. Subject signs an Form and is willing to participate in follow-up visits; 6. Primary and secondary endpoints.

Exclusion criteria

Exclusion criteria:

  1. Subject is diagnosed of headache with clear etiology.
  2. Subject had cerebral hemorrhage, bleeding events in other organs within 3 months or was in high risk of bleeding.
  3. Subject presents with ischemic lesions as indicated by brain CT/MR imaging.
  4. Subject is diagnosed of hepatic insufficiency: or AST>3× at the screening visit.
  5. Subject is diagnosed of moderate to severe renal insufficiency: \<30ml/min/1.73m2 at the screening visit.
  6. Subject has uncontrolled arrhythmia with clinical significance within 90 days.
  7. Subject is diagnosed of unstable angina, severe coronary atherosclerosis or myocardial infarction within 90 days.
  8. Subject is diagnosed of pulmonary artery embolism, peripheral artery embolism or deep Vein Thrombosis.
  9. Subject cannot follow the study procedure due to other acute or chronic diseases.
  10. Subject is pregnant or lactating.
  11. Subject is under other RCT.
  12. Subject has a \<1 year.
  13. Subject cannot follow the study procedure due to other reasons in the opinion of the investigators.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
440 participants (actual)

Study arms

  • Experimental
    PFO Closure Plus Antiplatelet Therapy

    Participants undergo transcatheter PFO closure and receive antiplatelet therapy according to the study protocol.

    Device: PFO closure device · Drug: Aspirin and clopidogrel · Drug: Triptans

  • Active comparator
    Antiplatelet Therapy Alone

    Participants receive antiplatelet therapy without planned PFO closure during the study period.

    Drug: Aspirin and clopidogrel · Drug: Triptans

Interventions

  • DevicePFO closure device

    Device PFO closure.

  • DrugAspirin and clopidogrel

    Drug pages: AspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ClopidogrelStudies of ClopidogrelClopidogrel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Aspirin 100mg qd for 6 months and clopidogrel 75mg qd administered for 1month after device implanted.

  • DrugTriptans

    If migraine recurred, Triptans would be administered during the acute phase.

06

What researchers measure

Primary outcomes

  1. Complete cessation of migraine

    Primary Efficacy Endpoint

    Time frame: Months 10-12

  2. Primary Safety Endpoint

    Serious adverse event related to the device, medication, or procedure

    Time frame: Within 12 Months

Secondary outcomes

  1. Change in Monthly Migraine Attack Frequency

    Change in the average number of migraine attacks per month from baseline.

    Time frame: Baseline to 12 months after randomization

  2. ≥50% Responder rate

    Proportion of participants achieving at least a 50% reduction in monthly migraine attack frequency compared with baseline.

    Time frame: Baseline to 12 months after randomization.

  3. Change in Headache Impact Test-6 (HIT-6) Score

    Change in HIT-6 score from baseline. Scores range from 36 to 78, with higher scores indicating greater headache-related impact.

    Time frame: Baseline to 12 months after randomization.

  4. Change in Migraine Disability Assessment (MIDAS) Score

    Change in MIDAS score from baseline, assessing migraine-related disability over the preceding 3 months. Higher scores indicate greater disability. This outcome was added through a protocol amendment dated August 3, 2024.

    Time frame: Baseline to 12 months after randomization.

Other outcomes

  1. Concomitant Medication Use

    Assessment of concomitant medications during the study, including acute migraine treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs), triptans, and other migraine-related medications.

    Time frame: Baseline through 12 months after randomization.

  2. Residual Right-to-Left Shunt After PFO Closure

    Assessment of residual right-to-left shunting following transcatheter PFO closure using contrast-enhanced transcranial Doppler ultrasonography (cTCD) and/or contrast echocardiography.

    Time frame: Six months after randomization.

07

Study locations

26 sites
08

References and documents

Publications

  • Zi-Yang Y, Hezhi L, Dongling L, Ximeng W, Caojin Z; SPRING Investigators. Rationale and design of the SPRING trail: effectivity and safety of Pfo closuRe vs medIcine in alleviatiNg migraine, a multicenter, randomized and open-label trail. BMC Cardiovasc Disord. 2024 Apr 5;24(1):198. doi: 10.1186/s12872-024-03866-3. PubMed 38580946 ↗

Individual participant data

Plan to share: No — The deidentified participant data will be shared on a request basis.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2021 to primary completion in Dec 2025, 52 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Sep 2025 → Dec 2025 and completion Sep 2025 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2021
First posted
Jul 1, 2021
StartActual
Aug 12, 2021
Primary completionActual
Dec 29, 2025was Sep 2025
CompletionActual
Dec 29, 2025was Sep 2025
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 12, 2026
Sites
6 sites added, 1 site removed
Show 6 added (6 China)
  • Dongguan Songshan Lake Tungwah Hospital · Dongguan, China
  • Guangdong Provincial Hospital of Chinese Medicine · Guangzhou, China
  • Xiangyang Central Hospital · Xiangyang, China
  • Jiangxi Provincial Peoples's Hospital · Nanchang, China
  • Tianjin Chest Hospital · Tianjin, China
  • Yan'an Hospital of Kunming City · Kunming, China
Show 1 removed
  • Tianjin Chest Hospital · Tianjin, China
Nov 12, 2026
Primary completion
Sep 6, 2025→Dec 29, 2025 (actual)
Nov 12, 2026
Study completion
Sep 6, 2025→Dec 29, 2025 (actual)
Nov 12, 2026
Eligibility
4 inclusion criteria edited, 1 added, 1 removed; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • AddedSubject is aged between 16 and 60 years old.
  • EditedEchocardiographySubject is diagnosed of PFO with right-to-left shunt, confirmed by Transthoracic echocardiography (TTE) or transesophageal echocardiography (TEE) with a bubble studyagitated saline contrast.
  • RemovedBubble study positive confirmed by transcranial doppler.
  • EditedPresenceSubject is diagnosed of PFO with right-to-left shunt, confirmed by Transthoracictranscranial doppler with agitated saline contrast.
  • EditedSubject is diagnosed of migraine without identifiable cause of headache.
  • EditedSubject signs an informed Consent Form and is willing to participate in follow-up visits; 6. Primary and secondary endpoints.
Exclusion criteria
  • ChangedBefore Brain CT/MR showed ischemic lesions.Now Subject presents with ischemic lesions as indicated by brain CT/MR imaging.
Nov 12, 2026
Interventions
Arms added: PFO Closure Plus Antiplatelet Therapy·Antiplatelet Therapy Alone; arms removed: Test Arm·Control Arm
Nov 12, 2026
Primary outcomes
1 edited, 1 time frame changed
What changed in the outcomes
  • ChangedBefore Serious Adverse Event (SAE) related due to device, drug or study procedureNow Primary Safety EndpointTime frame: Month 12 → Within 12 Months
  • Time frameComplete cessation of migraineMonth 12 → Months 10-12
Nov 12, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 38580946 ↗
Nov 12, 2026
Secondary outcomes
1 edited, 5 added, 2 removed
What changed in the outcomes
  • Edited≥50% Responder rateTime frame: Baseline and Month 12 → Baseline to 12 months after randomization.
  • AddedChange in Monthly Migraine Attack FrequencyTime frame: Baseline to 12 months after randomization
  • AddedChange in Headache Impact Test-6 (HIT-6) ScoreTime frame: Baseline to 12 months after randomization.
  • AddedChange in Migraine Disability Assessment (MIDAS) ScoreTime frame: Baseline to 12 months after randomization.
  • RemovedMonthly migraine attacksTime frame: Baseline and Month 12
  • RemovedMonthly migraine daysTime frame: Baseline and Month 12
  • Addedother outcomeConcomitant Medication UseTime frame: Baseline through 12 months after randomization.
  • Addedother outcomeResidual Right-to-Left Shunt After PFO ClosureTime frame: Six months after randomization.
Nov 12, 2026
Title
EffectivityEfficacy and Safety of PFO Closure vs MedicineMedical Therapy in Alleviating Migraine
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Active, not recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 38580946 ↗
    6 sites added, 1 site removed
    Show 6 added (6 China)
    • Dongguan Songshan Lake Tungwah Hospital · Dongguan, China
    • Guangdong Provincial Hospital of Chinese Medicine · Guangzhou, China
    • Xiangyang Central Hospital · Xiangyang, China
    • Jiangxi Provincial Peoples's Hospital · Nanchang, China
    • Tianjin Chest Hospital · Tianjin, China
    • Yan'an Hospital of Kunming City · Kunming, China
    Show 1 removed
    • Tianjin Chest Hospital · Tianjin, China
    Primary completion Sep 6, 2025→Dec 29, 2025 (now actual)
    Study completion Sep 6, 2025→Dec 29, 2025 (now actual)
    Eligibility 4 inclusion criteria edited, 1 added, 1 removed; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • AddedSubject is aged between 16 and 60 years old.
    • EditedEchocardiographySubject is diagnosed of PFO with right-to-left shunt, confirmed by Transthoracic echocardiography (TTE) or transesophageal echocardiography (TEE) with a bubble studyagitated saline contrast.
    • RemovedBubble study positive confirmed by transcranial doppler.
    • EditedPresenceSubject is diagnosed of PFO with right-to-left shunt, confirmed by Transthoracictranscranial doppler with agitated saline contrast.
    • EditedSubject is diagnosed of migraine without identifiable cause of headache.
    • EditedSubject signs an informed Consent Form and is willing to participate in follow-up visits; 6. Primary and secondary endpoints.
    Exclusion criteria
    • ChangedBefore Brain CT/MR showed ischemic lesions.Now Subject presents with ischemic lesions as indicated by brain CT/MR imaging.
    Primary outcomes 1 edited, 1 time frame changed
    What changed in the outcomes
    • ChangedBefore Serious Adverse Event (SAE) related due to device, drug or study procedureNow Primary Safety EndpointTime frame: Month 12 → Within 12 Months
    • Time frameComplete cessation of migraineMonth 12 → Months 10-12
    Secondary outcomes 1 edited, 5 added, 2 removed
    What changed in the outcomes
    • Edited≥50% Responder rateTime frame: Baseline and Month 12 → Baseline to 12 months after randomization.
    • AddedChange in Monthly Migraine Attack FrequencyTime frame: Baseline to 12 months after randomization
    • AddedChange in Headache Impact Test-6 (HIT-6) ScoreTime frame: Baseline to 12 months after randomization.
    • AddedChange in Migraine Disability Assessment (MIDAS) ScoreTime frame: Baseline to 12 months after randomization.
    • RemovedMonthly migraine attacksTime frame: Baseline and Month 12
    • RemovedMonthly migraine daysTime frame: Baseline and Month 12
    • Addedother outcomeConcomitant Medication UseTime frame: Baseline through 12 months after randomization.
    • Addedother outcomeResidual Right-to-Left Shunt After PFO ClosureTime frame: Six months after randomization.
    Interventions Arms added: PFO Closure Plus Antiplatelet Therapy·Antiplatelet Therapy Alone; arms removed: Test Arm·Control Arm
    Title EffectivityEfficacy and Safety of PFO Closure vs MedicineMedical Therapy in Alleviating Migraine
    + 4 other changes: verification date, oversight details, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04946734
Responsible party
Zhang Caojin, MD (Principal Investigator, Guangdong Provincial People's Hospital) — Principal investigator
First posted
Jul 1, 2021
Start date
Aug 12, 2021
Primary completion
Dec 29, 2025
Completion
Dec 29, 2025
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion